China Pharma Holdings CPHI · USD

Modern Traditional Chinese Medicines (“TCMs”), which are generally comprised of non-synthetic, plant-based medicinal compounds that have been widely used in the PRC for thousands of years. We apply modern production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules or powders.

Guidelines limit applications for identical products to three years post-initial approval, fostering innovation.

(Supplier-to-Business-to-Consumer) model, supported by digital tools, will enhance sales performance and market accessibility.

Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.

Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.

Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.

Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.

Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.

Quoted from its 10-K, filed 1 Apr 2026. Read the filing on SEC.gov ↗